tiprankstipranks
Genprex (DE:2DE1)
NASDAQ:2DE1

Genprex (2DE1) Price & Analysis

Followers

2DE1 Stock Chart & Stats

€3.96
€0.00(0.00%)
--

2DE1 FAQ

What was Genprex’s price range in the past 12 months?
Genprex lowest stock price was €3.96 and its highest was €7804.50 in the past 12 months.
    What is Genprex’s market cap?
    Genprex’s market cap is €3.46M.
      When is Genprex’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Genprex’s earnings last quarter?
      Genprex released its earnings results on May 15, 2019. The company reported -€0.124 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.124.
        Is Genprex overvalued?
        According to Wall Street analysts Genprex’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Genprex pay dividends?
          Genprex does not currently pay dividends.
          What is Genprex’s EPS estimate?
          Genprex’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Genprex have?
          Genprex has 504,935 shares outstanding.
            What happened to Genprex’s price movement after its last earnings report?
            Genprex reported an EPS of -€0.124 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
              Which hedge fund is a major shareholder of Genprex?
              Currently, no hedge funds are holding shares in DE:2DE1
              What is the TipRanks Smart Score and how is it calculated?
              Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                Company Description

                Genprex

                Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.

                Genprex (2DE1) Earnings & Revenues

                Similar Stocks
                Company
                Price & Change
                Follow
                Kazia Therapeutics
                Bolt Biotherapeutics
                Intensity Therapeutics, Inc.
                Popular Stocks